← Back to Screener
Marker Therapeutics, Inc. Common Stock (MRKR)
Price$1.66
Favorite Metrics
Price vs S&P 500 (26W)55.61%
Price vs S&P 500 (4W)14.39%
Market Capitalization$27.68M
All Metrics
Book Value / Share (Quarterly)$1.01
P/TBV (Annual)1.27x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-26.71%
Cash Flow / Share (Quarterly)$-0.72
Price vs S&P 500 (YTD)7.27%
Net Profit Margin (TTM)-342.96%
EPS (TTM)$-0.90
10-Day Avg Trading Volume0.21M
EPS Excl Extra (TTM)$-0.90
Revenue Growth (5Y)49.81%
EPS (Annual)$-0.79
ROI (Annual)-72.42%
Net Profit Margin (5Y Avg)-892.83%
Cash / Share (Quarterly)$0.96
Revenue Growth QoQ (YoY)-51.00%
ROA (Last FY)-63.78%
Revenue Growth TTM (YoY)-46.19%
EBITD / Share (TTM)$-0.84
ROE (5Y Avg)-87.35%
Operating Margin (TTM)-363.45%
Cash Flow / Share (Annual)$-0.72
P/B Ratio1.65x
P/B Ratio (Quarterly)1.48x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)3.27x
Net Interest Coverage (TTM)-0.22x
ROA (TTM)-67.05%
EPS Incl Extra (Annual)$-0.79
Current Ratio (Annual)8.39x
Quick Ratio (Quarterly)8.10x
3-Month Avg Trading Volume0.28M
52-Week Price Return53.70%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.90
P/S Ratio (Annual)7.80x
Asset Turnover (Annual)0.19x
52-Week High$4.07
Operating Margin (5Y Avg)-936.98%
EPS Excl Extra (Annual)$-0.79
Tangible BV CAGR (5Y)39.90%
26-Week Price Return64.36%
Quick Ratio (Annual)8.10x
13-Week Price Return-8.79%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.39x
Enterprise Value$11.609
Revenue / Share Growth (5Y)18.30%
Asset Turnover (TTM)0.20x
Book Value / Share Growth (5Y)-28.53%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-343.39%
Cash / Share (Annual)$0.96
3-Month Return Std Dev90.78%
Net Income / Employee (TTM)$-2
ROE (Last FY)-72.42%
Net Interest Coverage (Annual)-33.36x
EPS Basic Excl Extra (Annual)$-0.79
Receivables Turnover (TTM)6.31x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.90
Receivables Turnover (Annual)7.50x
ROI (TTM)-80.86%
P/S Ratio (TTM)7.80x
Pretax Margin (5Y Avg)-927.83%
Revenue / Share (Annual)$0.23
Tangible BV / Share (Annual)$2.33
Price vs S&P 500 (52W)18.61%
Year-to-Date Return11.41%
5-Day Price Return-4.60%
EPS Normalized (Annual)$-0.79
ROA (5Y Avg)-61.80%
Net Profit Margin (Annual)-342.96%
Month-to-Date Return27.69%
Cash Flow / Share (TTM)$-0.74
EBITD / Share (Annual)$-0.83
Operating Margin (Annual)-363.45%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-87.35%
EPS Basic Excl Extra (TTM)$-0.90
P/TBV (Quarterly)1.48x
P/B Ratio (Annual)1.48x
Pretax Margin (TTM)-343.39%
Book Value / Share (Annual)$1.01
Price vs S&P 500 (13W)-11.66%
Beta1.53x
Revenue / Share (TTM)$0.18
ROE (TTM)-80.86%
52-Week Low$0.81
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MRKRMarker Therapeutics, Inc. Common Stock | 7.80x | -46.19% | — | — | $1.66 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Marker Therapeutics is a clinical-stage immuno-oncology company developing T cell-based immunotherapies and vaccine candidates for hematological and solid tumors. Its MultiTAA T cell technology selectively expands patient-derived, tumor-specific T cells to target and eliminate cancer cells expressing tumor-associated antigens.